DoseMeRx vs InsightRX (2026)
The precision dosing shortlist, and a real one. Both compute doses for drugs where a wrong dose causes kidney injury or treatment failure, and both run Bayesian models updated on the patient's own measured levels. Both hold HITRUST certification. InsightRX is the more inspectable. Its models are named published models, and it publishes an analysis of 168,000 treatment courses across 117 hospital systems that compared models across patient groups and changed its default model as a result. DoseMeRx is built for the moment of dosing. It shows the pharmacist how well the model fits this patient's measured concentrations, which tells you when to distrust the answer, and it states exactly where patient data is stored. Neither holds an FDA clearance. InsightRX states that its Nova platform is not a device in the United States and was not submitted, so no regulator has reviewed the dose either product computes.
- The interface shows how well the model fits this patient's measured concentrations next to the recommended dose, so a pharmacist can see when the model is struggling.
- Residency is stated exactly: United States data in a Microsoft Azure facility in Illinois, and European data in EU data centers.
- It publishes how clinicians and scientists select and validate each drug model, alongside its HITRUST certification.
- The models are named published models, including Thomson and Goti, so a pharmacy can read the equations and derivation cohorts behind a dose.
- Its analysis of 168,000 treatment courses compared models across patient groups and changed the default, which is monitoring after deployment rather than validation before it.
- Integration is certified in the Epic marketplace rather than asserted.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DoseMeRx and InsightRX are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DoseMeRx | InsightRX |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | 2015 |
| Headquarters | Houston, Texas, United States | San Francisco, California, United States |
| Website | doseme-rx.com | insight-rx.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
InsightRX
-
Model / architecture
InsightRX released Gemini 2026.2, an update to the model selection engine in InsightRX Nova that adds a new general adult vancomycin model, McCarthy 2026, plus CKD-EPI eGFR versions of the published models that improved with that input.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
DoseMeRx is a Bayesian precision dosing platform for high risk medications, computing an individualized regimen from named, clinically validated population pharmacokinetic models, patient characteristics, measured drug concentrations and, where available, genotype.
Source: AI Health Index, September 2026
InsightRX builds model informed precision dosing software, which computes an individualized dose for a drug whose therapeutic window is narrow enough that getting it wrong causes harm. The core product, Nova, combines published population pharmacokinetic models with maximum a posteriori Bayesian forecasting: it starts from what is known about how a drug behaves in a population, updates that against the concentrations actually measured in this patient, and returns a regimen.
Source: AI Health Index, September 2026
Questions buyers ask
How do DoseMeRx and InsightRX work with the EHR?
The most consequential integration runs through another vendor's product: in October 2025 Inovalon announced a collaboration bringing DoseMeRx dosing into its pharmacy surveillance workflows, so the software reaches clinicians inside a surveillance platform as well as directly.
The applications are certified in the Epic Showroom with automatic patient data import, certified in the Oracle Cloud Marketplace for Oracle Health, and available for direct integration with MEDITECH Expanse, and the mechanism is SMART on FHIR rather than a proprietary interface, with InsightRX's implementation team validating data flow before go live. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do DoseMeRx and InsightRX cover?
In DoseMeRx's case, the function itself stays narrow: high risk medications with therapeutic drug monitoring.
For InsightRX, the library covers more than a hundred drugs and therapeutic areas spanning infectious disease, oncology and transplant. Age coverage extends to pediatrics, with a registered randomized pilot in a pediatric intensive care unit dosing vancomycin and amikacin. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for DoseMeRx and InsightRX?
With DoseMeRx, an independent 2018 comparison in Pharmacotherapy included DoseMe among five programs.
An independent group publishing in Pharmacotherapy in 2018 compared five Bayesian dose optimizing programs in critically ill patients and found InsightRX the most adaptable and best supported, while ranking another program as the least biased, so the independent comparison did not put this vendor first on accuracy. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How much do DoseMeRx and InsightRX leave to the clinician?
For DoseMeRx, the interface displays how well the model fits this patient's observed levels rather than presenting a dose as a bare number, tracks serum creatinine on the same page so renal trajectory is visible while the decision is made, and compares the individualized result against guideline recommendations.
With InsightRX, two disclosed design decisions concern what happens when the inputs are bad. Nova flags missing or stale data explicitly in the interface rather than silently computing on it, and pharmacists retain full manual data entry, so a broken feed or a record system outage degrades the workflow rather than blocking patient care. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither holds a United States device clearance, which is the usual position for therapeutic drug monitoring software, so the computed dose has not been reviewed by a regulator. Neither publishes a price. The independent 2018 comparison in Pharmacotherapy included both platforms and did not find them equivalent across every drug and scenario, so ask each vendor for results on the agents your service uses.
InsightRX states no HIPAA status and publishes no business associate terms, although it holds HITRUST r2. DoseMeRx publishes how it validates each drug model but no comparison of results across patient groups.